UFT Inhibits Lung Metastases in Spontaneous Metastasis Model of Lung Cancer

Abstract

Background: UFT, an oral 5-fluorouracil derivative, is the only drug that is effective as a postoperative adjuvant therapy for non-small cell lung cancer (NSCLC) [[3]], but the mechanism of the action remains unclear. We examined whether UFT and/or its metabolite, gamma-hydroxybutyric acid (GHB) inhibits lung metastases in a mouse model. Methods: Lewis lung carcinoma cells were implanted into the foot pads of C57 BL/6 mice, and mice were treated with UFT or GHB. Results: Both the mean number of metastatic nodules and the mean lung weight for UFT-treated mice (11.4 and 192.1 mg, respectively) were significantly lower than those for saline-treated mice (41.5 and 415.0 mg, respectively) (p < 0.001 for both). UFT did not inhibit tumor growth at the primary sites (foot pads). No significant body weight loss was documented in UFT-treated mice. GHB did not inhibit development of lung metastases even when a higher dose was used. Conclusions: UFT inhibits development of lung metastases without any toxicity in mouse model, which may explain the efficacy of postoperative administration of UFT for resected NSCLC.

Key words

UFT - non-small cell lung cancer - metastasis - mouse model

References

• 1 Mountain C F. Revisions in the international system for staging lung cancer.  Chest. 1997;  116 1710-1717
• 2 Tanaka F, Yanagihara K, Otake Y. et al . Surgery for non-small cell lung cancer: postoperative survival based on the revised tumor-node-metastasis classification and its time trend.  Eur J Cardiothorac Surg. 2000;  18 147-155
• 3 Wada H, Hitomi S, Teramatsu T. et al . Adjuvant chemotherapy after complete resection in non-small cell lung cancer.  J Clin Oncol. 1996;  14 1046-1054
• 4 Wada H, Miyahara R, Tanaka F. et al . Postoperative adjuvant chemotherapy with PVM (Cisplatin + Vindesine + Mitomycin C) and UFT (Uracil + Tegafur) in resected stage I - II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Surgery Group for Lung Cancer Surgery (WJSG).  Eur J Cardiothorac Surg. 1999;  15 438-443
• 5 The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu Japan) . A randomized trial of post operative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study).  Eur J Surg Oncol. 1995;  21 69-77
• 6 Kato H, Tsuboi M, Ohta M. et al . A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I (T1N0M0, T2N0N0) adenocarcinoma of the lung.  Proc ASCO. 2003;  22 621-(abstr. #2498)
• 7 Fujii S, Ikenaka K, Fukushima M. et al . Effect of Uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil.  Gann (Jpn J Cancer Res). 1978;  69 763-772
• 8 Yonekura K, Basaki Y, Chikahisa L. et al . UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.  Clin Cancer Res. 1999;  5 2185-2191
• 9 Basaki Y, Chikahisa L, Aoyagi K. et al . Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.  Angiogenesis. 2001;  4 163-173
• 10 Uchida J, Sato K, Okabe H. et al . Experimental postoperative adjuvant chemotherapy by UFT using primary tumor amputation model.  Int J Molecular Medicine. 2000;  5 357-362
• 11 Fujita F, Fujita M, Shimozuma K. et al . Analysis of factors influencing the chemosensitivity of human tumors xenografted into nude mice.  Jpn J Cancer Chemother. 1986;  13 3221-3228
• 12 Nio Y, Kimura H, Tsubono M. et al . A comparative study of anti tumor activities of 5′-deoxy-5-fluorouridine and its prodrug trimetoxy benzoyl-5′-deoxy-5-fluorouridine (Ro09 1390) on human digestive organ cancer xenograft lines transplanted into nude mice.  Anticancer Drugs. 1992;  3 387-393